Purine Analogues and Their Role in Methylation and Cancer Chemotherapy

  • Katherine L. Seley
  • Sylvester L. Mosley
Part of the Medical Intelligence Unit book series (MIUN)


Despite promising leads in the search for new chemotherapeutic agents, there remains an urgent need to develop more effective and less toxic drugs. Nucleosides and their corresponding nucleobases are the fundamental building blocks of many biological systems and as a result, have been extensively investigated due to their inherent structural resemblance to the naturally occurring nucleosides and nucleobases. Due to the intertwined relationship between purine and pyrimidine nucleotide metabolism, cell proliferation and tumor cell differentiation, inhibition of key enzymes in nucleotide metabolism and DNA synthesis can be used as a chemotherapeutic approach to treating cancer.


Purine Analogue African Swine Fever Virus Pyrimidine Nucleoside Squamous Carcinoma Cell Line NADH Cofactor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chu CK, Baker DC. Nucleosides and Nucleotides as Antitumor and Antiviral Agents. New York: Plenum Press; 1993.Google Scholar
  2. 2.
    Montgomery JA. Studies on the biologic activity of purine and pyrimidine analogs. Med Res Rev 1982; 2(3):271–308.PubMedCrossRefGoogle Scholar
  3. 3.
    Suhadolnik RJ. Nucleosides as Biological Probes. New York: Wiley Interscience; 1979.Google Scholar
  4. 4.
    Hatse S, De Clercq E, Balzarini J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem Pharmacol 1999; 58:539–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Montgomery JA, Bennett LL. Inhibitors of purine biosynthesis. In: Sandier M, Smith HJ, eds. Design of Enzyme Inhibitors as Drugs. Oxford: Oxford University Press; 1989.Google Scholar
  6. 6.
    Borchardt RT, Creveling CR, Ueland PM. Biological methylation and drug design. Clifton: Humana Press; 1986.Google Scholar
  7. 7.
    Szyf M. The DNA methylation machinery as a target for anticancer therapy. Pharmacol Ther 1996; 70(1):1–37.PubMedCrossRefGoogle Scholar
  8. 8.
    Nishimune Y, Koscik D, Nishina Y et al. Inhibition of DNA synthesis causes stem cell differentiation: induction of teratocarcinoma F9 cell differentiation with nucleoside analogues of DNA synthesis inhibitors and their inducing abilities counterbalanced specifically by normal nucleosides. Biochem Biophys Res Commun 1989; 163:1290–97.PubMedCrossRefGoogle Scholar
  9. 9.
    Marks PA, Rifkind RA. Differentiating factors. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Biological Therapy of Cancer. Philadelphia: Lippincott; 1991:754–62.Google Scholar
  10. 10.
    Szyf M. DNA methylation properties: consequences for pharmacology. Trends Pharmacol Sci 1994; 15:233–38.PubMedCrossRefGoogle Scholar
  11. 11.
    Banerjee AK. 5′-Terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev 1980; 44(2):175–205.PubMedGoogle Scholar
  12. 12.
    Szyf M. Targeting DNA methyltransferase in cancer. Cancer Metastasis Rev 1998; 17:219–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Wolfe MS, Borchardt RT. S-Adenosyl-L-homocysteine hydrolase as a target for antiviral chemotherapy. J Med Chem 1991; 34(5):1521–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Liu S, Wolfe MS, Borchardt RT. Rational approaches to the design of antiviral agents based on S-Adenosyl-L-homocysteine hydrolase as a molecular target. Antiviral Res 1992; 19:247–65.PubMedCrossRefGoogle Scholar
  15. 15.
    Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20:85–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Juttermann R, Li E, Jaenisch R. Toxicity of 5-Aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91:11797–801.PubMedCrossRefGoogle Scholar
  17. 17.
    Cantoni G. The Centrality of S-Adenosylhomocysteinase in the regulation of the biological utilization of S-adenosylmethionine. In: Borchardt RT, Creveling CR, Ueland PM, eds. Biological Methylation and Drug Design. Clifton: Humana Press; 1986:227–38.Google Scholar
  18. 18.
    Chiang PK. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol Ther 1998; 77(2):115–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Palmer JL, Abeles RH. The mechanism of action of S-adenosylhomocysteine. J Biol Chem 1979; 254(4):1217–26.PubMedGoogle Scholar
  20. 20.
    Turner MA, Yuan C-S, Borchardt RT et al. Structure determination of selenomethionyl S-adenosylhomocysteine hydrolase using data at a single wavelength. Nat Struct Biol 1998; 5(5):369–76.PubMedCrossRefGoogle Scholar
  21. 21.
    Hu Y, Komoto J, Huang Y et al. Crystal structure of S-adenosylhomocysteine hydrolase from rat liver. Biochemistry 1999; 38:8323–33.PubMedCrossRefGoogle Scholar
  22. 22.
    Yin D, Yang X, Hu Y et al. Substrate binding stabilizes S-adenosylhomocysteine hydrolase in a closed conformation. Biochemistry 2000; 39:9811–18.PubMedCrossRefGoogle Scholar
  23. 23.
    Yuan C-S, Liu S, Wnuk SF et al. Rational approaches to the design of mechanism-base inhibitors of S-adenosylhomocysteine hydrolase. Nucleosides & Nudeotides 1995; 14:439–47.Google Scholar
  24. 24.
    Yuan C-S, Liu S, Wnuk SF et al. Design and synthesis of S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. In: De Clercq E, ed. Advances in Antiviral Drug Design. Greenwich: JAI Press, Inc., 1996:41–88.Google Scholar
  25. 25.
    Turner MA, Yang X, Yin D et al. Structure and function of S-adenosylhomocysteine hydrolase. Cell Biochem Biophy 2000; 33:101–25.CrossRefGoogle Scholar
  26. 26.
    De Clercq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides & Nucleotides 1994; 13(6 & 7):1271–95.Google Scholar
  27. 27.
    Chiang PK, Burbelo PD, Brugh SA et al. Activation of collogen IV gene expression in F9 teratocarcinoma cells by 3-deazaadenosine analogs. J Biol Chem 1992; 267:4988–91.PubMedGoogle Scholar
  28. 28.
    Chiang PK, Cantoni GL. Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo. Biochem Pharmacol 1979; 28:1897–902.PubMedCrossRefGoogle Scholar
  29. 29.
    Bader JP, Brown NR, Chiang PK et al. 3-deazaadenosine, an inhibitor of adenosylhomocysteine hydrolase, inhibits reproduction of rous sarcoma virus and transformation of chick embryo cells. Virology 1978; 89:494–505.PubMedCrossRefGoogle Scholar
  30. 30.
    De Clercq E. S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem Pharmacol 1987; 36(16):2567–75.PubMedCrossRefGoogle Scholar
  31. 31.
    Pugh CSG, Borchardt RT. Effects of S-adenosylhomocysteine analogues on vaccinia viral messenger ribonucleic acid synthesis and methylation. Biochemistry 1982; 21:1535–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Svardal A, Djurhuus R, Ueland PM. Disposition of homocysteine and S-3-deazaadenosylhomocysteine in cells exposed to 3-deazaadenosine. Mol Pharmacol 1986; 30:154–58.PubMedGoogle Scholar
  33. 33.
    Bennett LL Jr, Brockman RW, Allan PW et al. Alterations in nucleotide pools induced by 3-deazaadenosine and related compounds. Biochem Pharmacol 1988; 37:1233–44.PubMedCrossRefGoogle Scholar
  34. 34.
    Chiang PK, Im YS, Cantoni GL. Phospholipids biosynthesis by methylations and choline incorporation: effect of 3-deazaadenosine. Biochem Biophys Res Commun 1980; 94:174–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Sherman ML, Shafman TD, Spriggs DR et al. Inhibition of murine erthroleukemia cell differentiation by 3-Deadeazaadenosi Cancer Res 1985; 45:5830–34.PubMedGoogle Scholar
  36. 36.
    Mizutani Y, Masuoka S, Imoto M et al. Induction of erthroid differentiation in leukaemic K562 cells by an S-adenosylhomocysteine hydrolase inhibitor, aristeromycin. Biochem Biophy Res Commun 1995; 207:69–74.CrossRefGoogle Scholar
  37. 37.
    Chiang PK. Conversion of 3T3-L1 fibroblasts to fat cells by an inhibitor of methylation: effect of 3-deazaadenosine. Science 1981; 211:1164–66.PubMedCrossRefGoogle Scholar
  38. 38.
    Paller AS, Arnsmeier SL, Clark SH et al. Z-4′,5′-Didehydro-5′-deoxy-5′-fluoroadenosine (MDL 28,842), and irreversible inhibitor of s-adenosylhomocysteine hydrolase, suppresses proliferation of cultured keratinocytes and squamous carcinoma cell lines. Cancer Res 1993; 53:6058–60.PubMedGoogle Scholar
  39. 39.
    De Clercq E. Carbocyclic adenosine analogues as s-adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances. Nucleosides & Nucleotides 1998; 17(1–3):625–34.Google Scholar
  40. 40.
    Glazer RI, Knode MC, Tseng CKH et al. 3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem Pharmacol 1986; 35(24):4523–27.PubMedCrossRefGoogle Scholar
  41. 41.
    Linevsky J, Cohen MB, Hartman KD et al. Effect of neplanocin A on differentiation, nucleic acid methylation, and c-myc mRNA expression in human promyelocytic leukemia cells. Mol Pharmacol 1985; 28:45–50.PubMedGoogle Scholar
  42. 42.
    Kishi T, Muroi M, Kusaka T et al. The structure of aristeromycin. Chem Pharm Bull 1972; 20:940–46.Google Scholar
  43. 43.
    Kusaka T, Yamamoto H, Shibata M et al. Streptomyces citricolor Nov. Sp. and a vew antibiotic, aristeromycin. J Antibiot 1968; 21(4):255–63.PubMedGoogle Scholar
  44. 44.
    Yaginuma S, Muto N, Tsujino M et al. Studies on neplanocin A, new antitumor antibiotic. I. producing organism, isolation and characterization. J Antibiot 1981; 34(4):359–66.PubMedGoogle Scholar
  45. 45.
    Hayashi M, Yaginuma S, Yoshioka H et al. Studies on neplanocin A, new antitumor antibiotic. II. structure determination. J Antibiot 1981; 34(6):675–80.PubMedGoogle Scholar
  46. 46.
    Wolfe MS, Lee Y, Bartlett WJ et al. 4′-modified analogues of aristeromycin and neplanocin A: synthesis and inhibitory activity toward S-adenosyl-L-homocysteine hydrolase. J Med Chem 1992; 35:1782–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Borchardt RT, Keller BT, Patel-Thombre U. Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 Cells. J Biol Chem 1984; 259(7):4353–58.PubMedGoogle Scholar
  48. 48.
    Glazer RI, Knode MC. Neplanocin A. A cyclopentyl analog of adenosine with specificity for inhibiting RNA methylation. J Biol Chem 1984; 259:12964–69.PubMedGoogle Scholar
  49. 49.
    Saunders PP, Tan M-T, Robins RK. Metabolism and action of neplanocin A in chinese hamster ovary cells. Biochem Pharmacol 1985; 34(15):2749–54.PubMedCrossRefGoogle Scholar
  50. 50.
    Borcherding DR, Scholtz SA, Borchardt RT. Synthesis of analogues of neplanocin A: utilization of optically active dihydroxycyclopentenones derived from carbohydrates. J Organic Chem 1987; 52:5457–61.CrossRefGoogle Scholar
  51. 51.
    Bennett LL Jr, Allan PW, Rose LM et al. Differences in the metabolism and metabolic effects of the carbocyclic adenosine analogs, neplanocin A and aristeromycin. Mol Pharmacol 1986; 29:383–90.PubMedGoogle Scholar
  52. 52.
    De Clercq E. Antiviral and antimetabolic activities of neplanocins. Antimicrob Agents Chemother 1985; 28(1):84–89.PubMedGoogle Scholar
  53. 53.
    Narayanan SR, Keller BT, Borcherding DR et al. 9-(trans-2′, trans-3′-Dihydroxycyclopent-4′-enyl) Derivatives of adenine and 3-deazaadenine: potent inhibitors of bovine liver S-adenosylhomocysteine hydrolase. J Med Chem 1988; 31:500–03.PubMedCrossRefGoogle Scholar
  54. 54.
    Ault-Riche DB, Lee Y, Yuan C-S et al. Effects of 4′-Modified analogs of aristeromycin on the metabolism of S-adenosyl-L-homocysteine in murine L929 cells. Mol Pharmacol 1993; 43:989–97.PubMedGoogle Scholar
  55. 55.
    Hasobe M, Hang H, Ault-Riche DB et al. (1′R, 2′S, 3′R)-9-(2′,3′-Dihydroxycyclopentan-1′-yl)-adenine and-3-Deaza-adenine: analogues of aristeromycin which exhibit potent antiviral activity with reduced toxicity. Antiviral Chem Chemother 1993; 4(4):245–48.Google Scholar
  56. 56.
    Hasobe M, McKee JG, Borcherding DR et al. 9-(trans-2′, trans-3′-Dihydroxycyclopent-4′-enyl)-adenine and-3-Deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity. Antimicrob Agents Chemother 1987; 31:1849–51.PubMedGoogle Scholar
  57. 57.
    Hasobe M, McKee JG, Borcherding DR et al. Effects of 9-(trans-2′, trans-3′-Dihydroxycyclopent-4′-enyl)-adenine and-3-Deazaadenine on the metabolism of S-adenosylhomocysteine in mouse L929 cells. Mol Pharmacol 1988; 33:713–20.PubMedGoogle Scholar
  58. 58.
    Hasobe M, McKee JG, Ishii H et al. Elucidation of the mechanism by which homocysteine potentiates the anti-vaccinia virus effects of the S-adenosylhomocysteine hydrolase inhibitor 9-(trans-2′, trans-3′-Dihydroxycyclopent-4′-enyl)-adenine. Mol Pharmacol 1989; 36:490–96.PubMedGoogle Scholar
  59. 59.
    Paisley SD, Hasobe M, Borchardt RT. Elucidation of the mechanism by which 9-(trans-2′, trans-3′-Dihydroxycyclopent-4′-enyl)-adenine inactivates S-adenosylhomocysteine hydrolase and elevates cellular levels of S-adenosylhomocysteine. Nucleosides & Nucleotides 1989; 8:689–98.Google Scholar
  60. 60.
    Cools M, De Clercq E. Correlation between the antiviral activity of acyclic and carbocyclic adenosine analogues in murine 1929 cells and their inhibitory effect on L929 cell S-adenosylhomocysteine hydrolase. Biochemical Pharmacology 1989; 38(7):1061–67.PubMedCrossRefGoogle Scholar
  61. 61.
    De Clercq E, Cools M, Balzarini J et al. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-Nor derivatives. Antimicrob Agents Chemother 1989; 33:1291–97.PubMedGoogle Scholar
  62. 62.
    Villalon MDG, Gil-Fernandez C, De Clercq E. Activity of several S-adenosylhomocysteine hydrolase inhibitors against african swine fever virus replication in vero cells. Antiviral Res 1993; 20:131–44.PubMedCrossRefGoogle Scholar
  63. 63.
    Tseng CKH, Marquez VE, Fuller RW et al. Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J Med Chem 1989; 32:1442–46.PubMedCrossRefGoogle Scholar
  64. 64.
    Glazer RI, Hartman KO, Knode MC et al. 3-deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 1986; 135:688–94.PubMedCrossRefGoogle Scholar
  65. 65.
    Bray M, Driscoll J, Huggins JW. Treatment of lethal ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000; 45:135–47.PubMedCrossRefGoogle Scholar
  66. 66.
    Secrist JA, III, Comber RN, Gray RJ et al. Synthesis of 5′-substituted analogues of carbocyclic 3-deazaadenosine as potential antivirals. J Medl Chem 1993; 36:2102–06.CrossRefGoogle Scholar
  67. 67.
    Cosstick R, Li X, Tuli DK. Molecular recognition in the minor groove of the DNA helix. Studies on the synthesis of oligonucleotides and polynucleotides containing 3-deaza-2′-deoxyadenosine. Nucleic Acids Res 1990; 18:4771–78.PubMedCrossRefGoogle Scholar
  68. 68.
    Houston DM, Dolence EK, Keller BT et al. Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 8. Molecular dissections of carbocyclic 3-deazaadenosine as inhibitors of S-adenosylhomocysteine hydrolase. J Med Chem 1985; 28:467–71.PubMedCrossRefGoogle Scholar
  69. 69.
    Aarbakke J, Miura GA, Prytz PS et al. Induction of HL-60 cell differentiation by 3-deaza-(±)-aristeromycin, an Inhibitor of S-adenosylhomocysteine hydrolase. Cancer Res 1986; 46:5469–72.PubMedGoogle Scholar
  70. 70.
    Vizirianakis IS, Tsiftsoglou AS. Induction of murine erythroleukemia cell differentiation is associated with methylation and differential stability of poly(A)= RNA transcripts. Biochimica et Biophysica Acta 1996; 1312:8–20.PubMedCrossRefGoogle Scholar

Copyright information

© and Kluwer Academic/Plenum Publishers 2005

Authors and Affiliations

  • Katherine L. Seley
    • 1
  • Sylvester L. Mosley
    • 1
  1. 1.School of Chemistry and BiochemistryGeorgia Institute of TechnologyAtlantaUSA

Personalised recommendations